During the past 65 years, IABS has responded to the need for constructive dialogue between official agencies and the biological product industry for humans and animals (vaccines, biotherapeutics, diagnostics, and cell & gene therapy). In that regard, we have worked successfully with, and have supplemented the activities of WHO, FDA, NIAID, EMA, OIE and others.
For more than 60 years, IABS has had a major impact on scientific and regulatory processes worldwide. These contributions have occurred primarily through collaborative scientific meetings and publications in the journal Biologicals. IABS’ unique role and strength reside in its ability to bring together interested parties for scientific discussions of important unresolved or emerging issues, to assist in developing a consensus and an action plan to achieve regulatory progress.

This strategy has led to significant gains in both the human and veterinary fields, and it differentiates IABS conferences from most scientific meetings that focus simply on the exchange of information. IABS is unique as a nonprofit neutral organization dedicated solely to addressing key issues in regulatory science that underpin approvals for vaccines and biopharmaceuticals worldwide.

Together, as a neutral platform with our conference partners and collaborators (private industry, academia, regulatory officials) we have held a variety of meetings on a broad spectrum of topics concerning the biological and biopharmaceutical arena, as well as the veterinary and human health fields. Another unique aspect of IABS conference is the final session which is dedicated to drafting consensus meeting summaries, conclusions & recommendations which are subsequently made available to interested parties such as regulatory agencies and the biological and biopharmaceutical industries. These recommendations have had a positive impact on the regulatory process in many cases.

SUCCESS STORIES
150 CONFERENCES ORGANIZED SINCE 1955

2017 & 2018
Workshops and Conferences

• Autogenous Vaccines and Their Role in Animal Health Strategy - Co-organized with University of Ghent - Belgium.

• 2nd Human Challenge Trials Workshop - Rockville, Maryland, USA.

• 1st Next Generation Sequencing Rockville, Maryland, USA.

• 4th Statistical and Data Management Approaches for Biotechnology Drug Development - Co-organized with FDA Rockville, Maryland, USA.

• 1st Meeting on Advancing Analytics for Biotechnology Drug Development Co-sponsored by NIST (National Institute of Standards and Technology) Gathersburg, Maryland, USA.

• Narcolepsy and Pandemic Influenza Vaccination: What we know and what we need to know before the next pandemic - Brussels, Belgium.

• 4th Cell Therapy Testing and Manufacturing Meeting - In collaboration with the California Institute for Regenerative Medicine (CIRM) - Los Angeles, California, USA.

• Implementing Non-animal Approaches to Human and Veterinary Vaccine Testing: Achieving scientific and regulatory success for rabies and beyond - Co-organized with NICEATM Bethesda, Maryland, USA.

• 5th Statistical Approaches for CMC Development and Lifecycle Management of Biotherapeutics and Vaccines - Rockville, Maryland, USA.
**BIOLOGICALS** is the IABS scientific journal, in which scholarly articles are peer reviewed and published.

**Biologics** provides a modern and multidisciplinary international forum for news, debate, and original research on all aspects of biologicals used in human and veterinary medicine. The journal publishes original papers, reviews, and letters relevant to the development, production, quality control, and standardization of biologicals derived from both novel and established biotechnologies. Special issues are produced to reflect topics of particular international interest and concern.

**Three types of papers are welcome**: original research reports, short papers, and review articles. The journal will also publish comments and letters to the editor, book reviews, meeting reports and information on regulatory issues.

**Research Areas in human and veterinary biologicals include:**

- Bacterial vaccines
- Blood products
- Cell biology
- Cell culture technology
- Cellular immunology
- Cytokines and allied mediators
- Diagnostics
- Downstream processing
- Gene transfer and expression
- General bacteriology
- General virology, endogenous and adventitious viruses
- Hormones
- Immunochemistry
- Molecular biology
- Monoclonal antibodies
- Parasitology
- Prion and prion disease
- Protein chemistry
- Toxins
- Toxoids
- Viral vaccines

---

### 2019 / 2020 Conferences & Workshops

- **Diagnostics in the Veterinary Field: The Role in Health Surveillance and Disease Identification**
  - May 15-17 – Wiesbaden, Germany

- **Towards Rabies Elimination in Asia-Pacific: From Theory to Practice**
  - September 25&26 – Bangkok, Thailand

- **Quality of Challenge Agent**
  - October 22 – Paul-Ehrlich Institute, Langen, Germany

- **2nd Next Generation Sequencing for Adventitious Virus Detection in Biologics**
  - November 13&14 – Ghent, Belgium

- **2nd Setting Specifications for Biological Products:**
  - December 2-3, 2019 - USP Headquarters, USA

- **Non-Animal Testing of Vaccines – A Global Congress**
  - December 3&4 – Bangkok, Thailand

- **3rd Human Challenge Trials Conference**
  - February 6&7 – Oxford, UK

- **IABS 65th Anniversary**
  - February 26-28 – Lyon, France
An independent, non-profit scientific organization, the Alliance is:

- Headquartered in Geneva, Switzerland, and governed by a Constitution and a Board of Directors
- Recognized as a non-profit organization in Switzerland, France and U.S.A.
- In an established working relationship with the World Health Organization (WHO) and World Organization for Animal Health (OIE).
- Has organized successful conferences & workshops with WHO and OIE as well as other partners such as: FDA\(^1\), NIH\(^2\), EMA\(^3\), USP\(^4\), PEI\(^5\), EDQM\(^6\), BMGF\(^7\).

1 Food & Drug Administration (USA); 2 National Institutes of Health (USA); 3 European Medicines Agency; 4 US Pharmacopeia; 5 Paul-Ehrlich Institut; 6 European Directorate for the Quality of Medicines and Healthcare; 7 Bill & Melinda Gates Foundation.

**Mission**

IABS is devoted to the scientific and medical advancement of biologicals, by facilitating communication among those who develop, produce and regulate biological products for human and animal health.

**Objectives**

- To provide a unique platform for discussion and the development of consensus positions on contemporary issues related to biologicals;
- To create an ongoing interface among leaders in clinical and basic research, biological product development, public health, manufacturing and regulation, by organizing scientific conferences and publishing reports of such meetings;
- To facilitate the establishment of international reference materials and the formulation of international guidance documents for biological substances used in human and veterinary medicine, through its conferences and publications;
- To promote uniform methods for establishing the international quality of biological products;
- To encourage research in connection with the characterization, standardization, quality, production, and clinical use of biological products.

IABS has two Affiliates: IABS Europe (IABS-EU) and IABS North America (IABS-NA)

For more information on the IABS organization, visit the IABS website: [www.iabs.org](http://www.iabs.org)

Please contact iabs@iabs.org with recommendations regarding topics for future IABS meetings